Aethlon Medical, Inc. (AEMD) 株式分析

企業概要

Aethlon Medical, Inc. is a medical therapeutic company dedicated to the development of novel immunotherapeutic devices designed to treat cancer and viral infections within the United States. The firm operates within the Healthcare sector, specifically in the Medical Devices industry, where it focuses on clinical-stage innovations such as the Hemopurifier intended for oncology applications and life-threatening viral infections. According to the latest available data, the company possesses a market capitalization of $3.48M and maintains a workforce consisting of 9 employees. These valuation and headcount figures indicate that the enterprise is a micro-cap entity with a very small operational footprint, suggesting it is in an early-stage development phase where capital allocation is heavily weighted toward research and development rather than commercial scale-up. The absence of reported annual revenue further contextualizes the company's position as a pre-revenue or early-revenue stage biotech firm, where value is derived from intellectual property potential rather than current cash generation.

財務健全性

The financial statements for Aethlon Medical, Inc. show a Net Income (TTM) of $-11,522,096 and an EBITDA of $-7,007,023, while the Revenue (TTM) is listed as N/A. The significant negative net income in the absence of reported revenue highlights a cost structure where operating expenses, likely driven by R&D and administrative overhead, substantially exceed any current sales, which is typical for companies in the clinical development phase. The company reports a Free Cash Flow of $-4,544,826, indicating that its current cash generation is negative, which implies limited financial flexibility and a reliance on external capital sources to fund ongoing operations. In terms of profitability metrics, the Gross Margin is 0.0%, the Operating Margin is 0.0%, and the Profit Margin is 0.0%; these zero margins reflect the pre-commercial nature of the business where costs are incurred before revenue recognition or are so high relative to negligible sales that margins cannot be calculated as a positive percentage. Regarding liquidity and leverage, the company holds $6.96M in cash against $417,522 in debt, resulting in a Debt to Equity ratio of 6.22, which suggests a highly leveraged balance sheet relative to its equity base, although the absolute dollar value of debt is low compared to cash reserves. The Current Ratio stands at 5.68, a figure that indicates strong short-term liquidity and suggests the company has ample current assets to cover its current liabilities, providing a buffer against immediate solvency risks despite the negative earnings. Finally, the Return on Equity is -208.6% and the Return on Assets is -62.9%, revealing that management is currently utilizing shareholder and asset bases to generate significant losses rather than returns, a common characteristic for early-stage biotechnology firms burning cash to achieve product milestones.

バリュエーション評価

The valuation metrics for Aethlon Medical, Inc. present a trailing P/E Ratio (TTM) of N/A and a Forward P/E of -2.27. The discrepancy between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in future earnings recovery but cannot yet value the stock based on historical profitability due to the lack of positive earnings. The Price to Book ratio is recorded at 0.32, which indicates that the market values the company at a significant discount to its book value, reflecting the high risk associated with its unproven clinical assets and the potential for substantial further dilution if equity financing is required. Alternative valuation measures such as the Price to Sales ratio are listed as N/A, and the EV/EBITDA is 0.52; these figures suggest that the company is trading at a multiple that is heavily influenced by its cash position and the specific valuation norms for pre-revenue medical device companies rather than traditional earnings multiples. The 52-week high for the stock is $35.20 and the 52-week low is $1.36, placing the current trading environment within a highly volatile range where the stock price has experienced extreme fluctuation over the past year. The Beta value is 1.52, which signifies that the stock's price volatility is approximately 52% higher than that of the broader market, making it a high-risk investment suitable only for portfolios with a high tolerance for biotech-specific price swings.

Growth & Income

The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet generated sufficient scale to report comparable growth rates. In the absence of positive earnings growth, the company is not in a position to sustain a dividend payout, which is confirmed by a Dividend Yield of N/A and a Payout Ratio of 0.0%. Consequently, the company does not pay dividends to shareholders; instead, it operates under a strategy of reinvesting its existing cash reserves and seeking external funding to fuel research and development efforts toward its immunotherapeutic devices. This growth and income profile characterizes Aethlon Medical, Inc. as a pure-play speculative asset where returns are derived solely from potential future commercialization success rather than current cash distributions or consistent earnings expansion.